Combination molecular therapies for type 1 spinal muscular atrophy-Reference-Cited by-同舟云学术

Combination molecular therapies for type 1 spinal muscular atrophy

Published:2020-08-10 Issue:4 Volume:62 Page:550-554
ISSN:0148-639X
Container-title:Muscle & Nerve
language:en
Short-container-title:Muscle Nerve

Author:

Harada Yohei¹,Rao Vamshi K.²,Arya Kapil³,Kuntz Nancy L.²,DiDonato Christine J.²,Napchan‐Pomerantz Galia⁴,Agarwal Amit⁵,Stefans Vikki⁶,Katsuno Masahisa⁷^ORCID,Veerapandiyan Aravindhan³^ORCID

Affiliation:

1. Department of Neurology University of Arkansas for Medical Sciences Little Rock Arkansas USA

2. Division of Neurology, Department of Pediatrics Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine Chicago Illinois USA

3. Division of Neurology, Department of Pediatrics Arkansas Children's Hospital, University of Arkansas for Medical Sciences Little Rock Arkansas USA

4. Department of Pediatric Pulmonology Joe DiMaggio Children's Hospital Hollywood Florida USA

5. Division of Pulmonology, Department of Pediatrics Arkansas Children's Hospital, University of Arkansas for Medical Sciences Little Rock Arkansas USA

6. Department of Pediatrics and Physical Medicine and Rehabilitation Arkansas Children's Hospital, University of Arkansas for Medical Sciences Little Rock Arkansas USA

7. Department of Neurology Nagoya University Graduate School of Medicine Nagoya Japan

Publisher

Wiley

Subject

Physiology (medical),Cellular and Molecular Neuroscience,Clinical Neurology,Physiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/mus.27034

Reference19 articles.

1. U.S. Food and Drug Administration. AveXis Inc Zolgensma (onasemnogene abeparvovec‐xioi). [online].https://www.fda.gov/vaccines-blood-biologics/zolgensma. Accessed July 19 2020.

2. U.S. Food and Drug Administration USFaD. SPINRAZA (nusinersen) injection for intrathecal use. [online].https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209531lbl.pdf. Accessed July 19 2020.

3. New treatments in spinal muscular atrophy: an overview of currently available data

4. VeerapandiyanA.Spinal muscular atrophy. MedLink Neurology. July 5 2019. MedLink Corporation.2019.

5. An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world multidisciplinary outcomes of onasemnogene abeparvovec monotherapy in patients with spinal muscular atrophy type 1: experience of the French cohort in the first three years of treatment;Orphanet Journal of Rare Diseases;2024-09-13

2. Newborn Screening for Spinal Muscular Atrophy: Variations in Practice and Early Management of Infants with Spinal Muscular Atrophy in the United States;International Journal of Neonatal Screening;2024-08-16

3. Systematic Review of Presymptomatic Treatment for Spinal Muscular Atrophy;International Journal of Neonatal Screening;2024-08-14

4. Transforming care for spinal muscular atrophy: A critical look at treatment paradigms;Molecular Therapy;2024-08

5. Clinical perspectives: Treating spinal muscular atrophy;Molecular Therapy;2024-08